RAHWAY, N.J., July 26, 2024--Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Padcev as First-Line Treatment for Patients With Advanced Bladder Cancer
RAHWAY, N.J., July 23, 2024--Merck Announces Fourth-Quarter 2024 Dividend
Key Insights Significantly high institutional ownership implies Merck's stock price is sensitive to their trading...